ViroGates has received a 6.6 million DKK grant from the EU Horizon 2020 program. This grant will fund a project aimed at optimizing hospital resources and ensuring early therapeutic intervention for COVID-19 patients using suPARnostic®. The project’s goal is to better classify patients’ clinical risks at emergency departments for efficient management of COVID-19 symptoms.

The project will focus on distinguishing low-risk patients who can be safely discharged sooner and identifying those who would benefit from prompt clinical intervention using two therapeutic drugs.

Additionally, the grant will help ViroGates move part of its suPARnostic® TurbiLatex manufacturing to Europe, enhancing its supply chain.

Research has already indicated that suPARnostic® is highly effective in determining which patients can be discharged without the risk of the disease worsening. Early intervention based on other COVID-19 drug studies is crucial for combating the effects of the disease.

Jakob Knudsen, CEO of ViroGates, expressed enthusiasm for the EU’s support in aiding medical professionals make informed discharge decisions for COVID-19 patients. He emphasized the importance of suPARnostic® as a prognostic biomarker with a strong ability to predict low risks of respiratory failure.

Knudsen also highlighted the importance of guiding therapeutic interventions with drugs under development for COVID-19 treatment. He stressed that early intervention and drug prioritization are key to successful outcomes, considering their costs and potential side effects.